Cargando…

Changes in body composition and lipid profile in prostate cancer patients without bone metastases given Degarelix treatment: the BLADE prospective cohort study

BACKGROUND: Luteinizing hormone-releasing hormone (LHRH)-agonists in prostate cancer (PCa) patients induce sarcopenic obesity. The effect of LHRH-antagonist on body composition has never been explored. We evaluated changes in fat (FBM) and lean body mass (LBM) in PCa patients undergoing Degarelix. M...

Descripción completa

Detalles Bibliográficos
Autores principales:	Palumbo, Carlotta, Antonelli, Alessandro, Triggiani, Luca, Dalla Volta, Alberto, Maffezzoni, Filippo, Zamboni, Stefania, Borghetti, Paolo, Rinaudo, Luca, Valcamonico, Francesca, Maroldi, Roberto, Magrini, Stefano Maria, Simeone, Claudio, Berruti, Alfredo
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2021
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7958940/ https://www.ncbi.nlm.nih.gov/pubmed/33723362 http://dx.doi.org/10.1038/s41391-021-00345-0

Ejemplares similares

Maintenance of androgen deprivation therapy or testosterone supplementation in the management of castration-resistant prostate cancer: that is the question
por: Caramella, Irene, et al.
Publicado: (2022)

Association of Fat Body Mass With Vertebral Fractures in Postmenopausal Women With Early Breast Cancer Undergoing Adjuvant Aromatase Inhibitor Therapy
por: Pedersini, Rebecca, et al.
Publicado: (2019)

The Interaction of Lean Body Mass With Fat Body Mass Is Associated With Vertebral Fracture Prevalence in Women With Early Breast Cancer Undergoing Aromatase Inhibitor Therapy
por: Monteverdi, Sara, et al.
Publicado: (2020)

Evaluation of degarelix in the management of prostate cancer
por: Van Poppel, Hendrik
Publicado: (2010)

When Less Is More: Specific Capture and Analysis of Tumor Exosomes in Plasma Increases the Sensitivity of Liquid Biopsy for Comprehensive Detection of Multiple Androgen Receptor Phenotypes in Advanced Prostate Cancer Patients
por: Foroni, Chiara, et al.
Publicado: (2020)

Bone metastases from head and neck malignancies: Prognostic factors and skeletal-related events
por: Grisanti, Salvatore, et al.
Publicado: (2019)

Degarelix and its therapeutic potential in the treatment of prostate cancer
por: Doehn, Christian, et al.
Publicado: (2009)

Case Report: 18F-PSMA PET/CT Scan in Castration Resistant Prostate Cancer With Aggressive Neuroendocrine Differentiation
por: Bergamini, Marco, et al.
Publicado: (2022)

Treatment paths for localised prostate cancer in Italy: The results of a multidisciplinary, observational, prospective study (Pros-IT CNR)
por: Buglione, Michela, et al.
Publicado: (2019)

Investigation of the GnRH antagonist degarelix isomerization in biological matrices
por: Ferrazzano, Lucia, et al.
Publicado: (2023)

Differential Diagnosis and Clinical Management of a Case of COVID-19 in a Patient With Stage III Lung Cancer Treated With Radio-chemotherapy and Durvalumab
por: Guerini, Andrea Emanuele, et al.
Publicado: (2020)

An update on the use of degarelix in the treatment of advanced hormone-dependent prostate cancer
por: Rick, Ferenc G, et al.
Publicado: (2013)

Degarelix treatment is compatible with diabetes and antithrombotic therapy in patients with prostate cancer
por: Tokiwa, Suguru, et al.
Publicado: (2017)

Efficacy of Degarelix in the Neoadjuvant Setting in Managing Locally Advanced Prostate Cancer
por: Sankaran, Sindhu, et al.
Publicado: (2023)

Reply to ‘Comment on ‘Efficacy of stereotactic body radiotherapy in oligorecurrent and in oligoprogressive prostate cancer: new evidence from a multicentric study’’
por: Triggiani, Luca, et al.
Publicado: (2018)

Response to Degarelix After Resistance to Leuprolide in a Patient With Metastatic Prostate Cancer
por: Lazenby, Mark
Publicado: (2012)

Prostate Cancer-Associated Disseminated Intravascular Coagulation with Excessive Fibrinolysis Treated with Degarelix
por: Ong, Shawn Y., et al.
Publicado: (2015)

Mistaken administration of a repeat loading dose of Degarelix leading to acute psychosis
por: Hamdoon, Musaab, et al.
Publicado: (2021)

Role of Body Composition in the Prediction of Skeletal Fragility Induced by Hormone Deprivation Therapies in Cancer Patients
por: Dalla Volta, Alberto, et al.
Publicado: (2023)

The Spread of SARS-CoV-2 Infection Among the Medical Oncology Staff of ASST Spedali Civili of Brescia: Efficacy of Preventive Measures
por: Dalla Volta, Alberto, et al.
Publicado: (2020)

Assessment of DXA derived bone quality indexes and bone geometry parameters in early breast cancer patients: A single center cross-sectional study
por: Pedersini, Rebecca, et al.
Publicado: (2023)

Real-world Cardiovascular Outcomes Associated With Degarelix vs Leuprolide for Prostate Cancer Treatment
por: Wallach, Joshua D., et al.
Publicado: (2021)

Degarelix vs. leuprorelin for the treatment of prostate cancer in China: A cost-utility analysis
por: Yan, Jianzhou, et al.
Publicado: (2022)

The Effects of Chemical Castration with Degarelix on Bone Turnover: Densitometric and Biomechanics Bone Properties of Male Rats
por: Jayusman, Putri Ayu, et al.
Publicado: (2018)

Cardiovascular Safety of Degarelix Versus Leuprolide for Advanced Prostate Cancer: The PRONOUNCE Trial Study Design
por: Melloni, Chiara, et al.
Publicado: (2020)

Does Exist a Differential Impact of Degarelix Versus LHRH Agonists on Cardiovascular Safety? Evidences From Randomized and Real-World Studies
por: Sciarra, Alessandro, et al.
Publicado: (2021)

Response of Degarelix treatment in human prostate cancer monitored by HR-MAS (1)H NMR spectroscopy
por: Madhu, Basetti, et al.
Publicado: (2016)

Efficacy and safety of degarelix in patients with prostate cancer: Results from a phase III study in China
por: Sun, Yinghao, et al.
Publicado: (2020)

Patients and physician satisfaction of Degarelix in androgen deprivation therapy for advanced hormone-dependent prostate cancer in the Netherlands
por: Roshani, Hossain, et al.
Publicado: (2021)

Effects of Docetaxel plus Degarelix on Quality of Life and Vascular Endothelial Growth Factor in Patients with Prostate Cancer
por: Li, Weiping, et al.
Publicado: (2022)

Degarelix for the treatment of advanced prostate cancer compared with GnRh-Agonists: a systematic review and meta-analysis
por: Hosseini, Seyed Alireza, et al.
Publicado: (2016)

In Search of the Molecular Mechanisms Mediating the Inhibitory Effect of the GnRH Antagonist Degarelix on Human Prostate Cell Growth
por: Sakai, Monica, et al.
Publicado: (2015)

Real-World Evidence Prediction of a Phase IV Oncology Trial: Comparative Degarelix vs Leuprolide Safety
por: Merola, David, et al.
Publicado: (2022)

Lectures given at the 3rd Session of the Centro Internazionale Matematico Estivo (C.I.M.E.)
por: Simeone, Bruno
Publicado: (1989)

Whole brain radiotherapy with adjuvant or concomitant boost in brain metastasis: dosimetric comparison between helical and volumetric IMRT technique
por: Borghetti, Paolo, et al.
Publicado: (2016)

Blade runner
Publicado: (1996)

Efficacy and safety of 3‐month dosing regimen of degarelix in Japanese subjects with prostate cancer: A phase III study
por: Ozono, Seiichiro, et al.
Publicado: (2018)

Mebendazole as a Candidate for Drug Repurposing in Oncology: An Extensive Review of Current Literature
por: Guerini, Andrea Emanuele, et al.
Publicado: (2019)

Efficacy of the EDP-M Scheme Plus Adjunctive Surgery in the Management of Patients with Advanced Adrenocortical Carcinoma: The Brescia Experience
por: Laganà, Marta, et al.
Publicado: (2020)

Inhibitory effects of long-term repeated treatments of a sustainable GnRH antagonist, degarelix acetate, on caprine testicular functions
por: KAWATE, Noritoshi, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_66pm8uiqf4g5f6toa3qm3r4dvj